Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T22:19:06.221Z.
Calculation as of: 2026-10-06T22:19:06.221Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9ce6fbcd26cd45408ca5c48bb89acec7413e4f513cf2411d103b895814b8ecfc
EARNINGS YIELD
N/A
Market Cap
$1.89B
Earnings Yield
2.65%
TTM Avg
2.81%
3Y Avg
2.81%
5Y Avg
0.91%
Market Cap
$1.89B
Earnings Yield
N/A
TTM Avg
31.62%
3Y Avg
31.62%
5Y Avg
31.62%
Market Cap
$1.83B
Earnings Yield
2.21%
TTM Avg
1.44%
3Y Avg
2.50%
5Y Avg
2.86%
Market Cap
$1.83B
Earnings Yield
N/A
TTM Avg
1.03%
3Y Avg
1.02%
5Y Avg
1.02%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Trevi Therapeutics, Inc. (TRVI) | $1.87B | N/A | N/A | N/A | N/A |
| Novavax, Inc. (NVAX)vs › | $1.86B | N/A | 28.68% | 28.68% | 28.68% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 2.65% | 2.81% | 2.81% | 0.91% |
| Zymeworks Inc. (ZYME)vs › | $1.89B | N/A | 31.73% | 31.73% | 31.73% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | N/A | 31.62% | 31.62% | 31.62% |
| Immunome, Inc. (IMNM)vs › | $1.85B | N/A | N/A | N/A | N/A |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.84B | N/A | N/A | N/A | N/A |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | 2.21% | 1.44% | 2.50% | 2.86% |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.83B | N/A | 1.03% | 1.02% | 1.02% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.92B | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
